IGF-1 LR3
NeuroprotectionNeurology research on IGF-1 LR3 examines whether this modified insulin-like growth factor 1 produces measurable CNS effects beyond peripheral activity. The cognitive case rests on three convergent threads: binds the igf-1 receptor with full agonist activity the n-terminal extension (lr3 — long arginine-3) prevents binding to igf-binding proteins, so circulating lr3 remains 'free' and bioactive. drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models.; downstream consequences for monoamine and neurotrophic signalling; and reduction of chronic neuroinflammation. IGF-1 LR3 is dosed at 20-50 mcg 1-2x daily subq via subq in cognitive-focused protocols, with the ~20-30 hr (vs ~10 min for native IGF-1) pharmacokinetic profile shaping receptor occupancy timing.
Key Takeaways
Cognitive lens: IGF-1 LR3 acts as a restorative compound rather than a stimulant for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: Binds the IGF-1 receptor with full agonist activity. Neuro dose: 20-50 mcg 1-2x daily subq via subq; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Selank, Semax + Selank Blend.
Binds the IGF-1 receptor with full agonist activity. The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. For cognitive endpoints specifically, this mechanism translates into restorative rather than stimulant effects: reduction of neuroinflammation, support for BDNF and NGF signalling, modulation of monoamine systems, and stabilisation of cerebral perfusion. The three subsections below examine IGF-1 LR3's CNS access route, the neurotrophic and inflammatory effects, and the receptor-level pharmacology.
Cerebral perfusion and the structural cognitive substrate
Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. IGF-1 LR3, with its Binds the IGF-1 receptor with full agonist activity The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The ~20-30 hr (vs ~10 min for native IGF-1) pharmacokinetic profile supports this restorative rather than stimulant phenotype.
Pharmacokinetics and cognitive dose timing
The ~20-30 hr (vs ~10 min for native IGF-1) half-life of IGF-1 LR3 via subq administration sets the timing window for cognitive effects. At 20-50 mcg 1-2x daily subq, receptor occupancy curves and CNS exposure align with the typical multi-week onset profile reported by cognitive-focused users. The standard 1-2x daily subq dosing pattern is calibrated to maintain therapeutic exposure without continuous saturation, preserving the natural rhythm of the targeted system.
Receptor pharmacology and selectivity profile
IGF-1 LR3's receptor-level pharmacology determines its selectivity profile and its overlap with companion peptides. Binds the IGF-1 receptor with full agonist activity. The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. The selectivity (or lack thereof) for the principal target relative to off-target receptors is the basis for both the clinical phenotype and the side-effect profile. In stack design this matters: pairing IGF-1 LR3 with peptides engaging the same primary receptor produces competition rather than synergy.
Where IGF-1 LR3 is used for hpa axis modulation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
Stroke Recovery is one of the more-reported subjective benefits of IGF-1 LR3 across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
For post-tbi recovery, IGF-1 LR3 is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Where IGF-1 LR3 is used for serotonin modulation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 20-50 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 12-50 mcg | 4–6 weeks initial cycle |
| Neuroprotection focus | SubQ | 20-50 mcg | 1-2x daily SubQ |
| Maintenance phase | SubQ | 14-50 mcg | Ongoing with periodic pauses |
Dose timing for IGF-1 LR3 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
IGF-1 LR3 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- IGF-1 LR3 + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with IGF-1 LR3's mechanism in cognitive / neurological protocols.
- IGF-1 LR3 + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with IGF-1 LR3's mechanism in cognitive / neurological protocols.
- IGF-1 LR3 + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with IGF-1 LR3's mechanism in cognitive / neurological protocols.
- IGF-1 LR3 + DSIP: Mechanism remains incompletely characterised. Pairs naturally with IGF-1 LR3's mechanism in cognitive / neurological protocols.
Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy.
Lens-specific safety considerations for cognitive / neurological use of IGF-1 LR3: Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| IGF-1 LR3 | Modified insulin-like growth factor 1 | ~20-30 hr (vs ~10 min for native IGF-1) | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder |
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience |
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models |
Does IGF-1 LR3 cross the blood-brain barrier?
Can IGF-1 LR3 be stacked with other nootropics?
Is IGF-1 LR3 a true nootropic?
How long until I notice cognitive effects?
What should I look for in IGF-1 LR3 sourcing and quality?
What is the standard dosing protocol for IGF-1 LR3?
Start a IGF-1 LR3 Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified IGF-1 LR3 and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- 9111 Da
- Sequence length
- 83 aa
- Half-life
- ~20-30 hr (vs ~10 min for native IGF-1)
- WADA
- Banned (S2)
- FDA
- Unapproved (research reagent)
- Research
- Animal models; off-label use widespread
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for IGF-1 LR3 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for IGF-1 LR3
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised